KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Shares of Kodiak Sciences (KOD) broke into September’s top five biotech gainers on a key eye drug win. Still, investor Martin Shkreli questioned whether it can outshine Eylea, Regeneron’s established treatment for wet age-related macular degeneration (AMD).KOD stock soared 178% on Monday to $89.92…